VersaCut+ Morcellator

1. VERSACUT+™
Tissue Morcellator
All the benefits you have come to rely on with
the current VersaCut tissue morcellator are
now enhanced with the new VersaCut+.
The Ideal Complementary Tool for Holmium
Laser Enucleation of the Prostate (HoLEP)
SAFER FASTER
MORE INTUITIVE AND
USER-FRIENDLY
MORE COST-EFFECTIVE
VersaCut+ Enhanced Benefits:
Reduced procedure time: A unique mechanism
shortens the system’s response time when
suction and morcellation are activated
• Light weight and portable handpiece
• Two ergonomically designed reusable
handpieces for a better grip: Regular or
inverted, according to your preference
• A compatible tissue collection disposable kit
and holder are provided with the system
• Improved and more reliable motor and blades to maximize
the system’s life cycle and minimize maintenance costs
• Validated autoclave sterilization and enzymatic/alkaline
cleaning of handpieces and blades
• Two sets of blades allowing continuous usage of the device
Improved stability and control:
Handpiece and blades are fixed,
minimizing the oscillating movement of
the blades during the procedure
TISSUE MORCELLATOR

2. References:
1. Gilling PJ et al., Holmium laser enucleation of the prostate (HoLEP) combined
with transurethral tissue morcellation: an update on the early clinical experience, J
Endourol, 1998, 12:457-9.
2. Gilling PJ ,HoLEP vs. TURP Reoperation Rates and Cost Effectiveness, presented
material at WCE and AUA 2009.
3. Ehab A. Elzayat, Mostafa M. Elhilali, Holmium Laser Enucleation of the Prostate
(HoLEP): Long-Term Results, Reoperation Rate, and Possible Impact of the Learning
Curve, European Urology, 2007, 52(1465-1472).
4. Gilling PJ et al, Long-term results of a randomized trial comparing holmium laser
enucleation of the prostate and transurethral resection of the prostate: results at 7
years. BJU Int 2012; 109(3): 408-11.
5. Elmansy H et al, Holmium Laser Enucleation Versus Photoselective Vaporization
for Prostatic Adenoma Greater than 60 Ml: Preliminary Results of a Prospective,
Randomized Clinical Trial. J Urol 2012; 188: 216-221.
6. Ahyai S et al, Holmium Laser Enucleation versus Transurethral Resection of the
Prostate: 3-Year Follow-Up Results of a Randomized Clinical Trial. Eur Urol 2007;
52(5):1456-63.
7. Tasçı AI, Ilbey YÖ, Luleci H et al: 120-W Green-Light laser photoselective
vaporization of prostate for benign prostatic hyperplasia: midterm outcomes, Urology
2011; 78: 134.
8. Gupta M et al, Comparison of standard transurethral resection, transurethral vapour
resection and holmium laser enucleation of the prostate for managing benign
prostatic hyperplasia of > 40 g. BJU Int 2006; 97:85-9.
9. Vavassori I., et al, Three year outcome following Holmium Laser Enucleation of the
Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients,
European Urology, 2007.
© 2014 All Rights Reserved. The Lumenis Group of Companies. PB-1004392 Rev BSURGICAL .lumenis.com
AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 3999
EMEA
Dreieich Dreieichenhain,
Germany
T +49 6103 8335 0
F +49 6103 8335 300
Roma (RM), Italy
T +39 06 90 75 230
F +39 06 90 75 269
Hertfordshire, UK
T +44 20 8736 4110
F +44 20 8736 4119
JAPAN
Tokyo, Japan
T +81 3 4431 8300
F +81 3 4431 8301
ASIA / PACIFIC
Beijing, China
T + 86 10 5737 6677
Gurgaon, India
T + 91 124 422 07 95
Kowloon, Hong Kong
T + 852 217 428 00
F + 852 272 251 51
HoLEP was first introduced by Peter Gilling, MD1
as an alternative
technique for treating benign prostatic hyperplasia (BPH), and
subsequently became its gold standard treatment. Among its
advantages are low reoperation rates, safety, and a wide patient
applicability 2,3
. Compared to alternative treatment options for BPH,
HoLEP is more efficient 4,5
, safer 6,7
and more cost-effective 8
.
Lumenis is recognized as the only company in the world that
supports, promotes and contributes to the adoption of HoLEP.
This unique recognition has been obtained due to Lumenis’
ongoing support of HoLEP for over 15 years.
“Lumenis is the company, which supports, promotes
and assists in Enucleation adoption more than any other
company worldwide.”
Mr. Peter Gilling, Consultant Urologist, Tauranga Hospital and Grace
Hospital, Tauranga, New Zealand.
Lumenis has utilized its extensive experience with HoLEP to
anticipate your unmet HoLEP needs, leading to the development
of the new VersaCut+ tissue morcellator.
The new VersaCut+ tissue morcellator system is a complementary
accessory to the new Lumenis Pulse™ 120H holmium laser
platform, and is ideal for the removal of resected prostate tissue
from the bladder during HoLEP.
“The VersaCut+ Morcellator is much faster than the current
version. The morcellation rates are halved and the handpiece
is much more ergonomic, lighter and easier to use.”
Mr. Tev Aho, Consultant Urologist, Cambridge University NHS Trust, U.K.
Legacy of Contribution
Specifications
Product number GA-0007500 VersaCut+ System with Inverted H/P
GA-0007600 VersaCut+ System with Regular H/P
AC-1137540 VersaCut+ Disp. Kit (6-Pack)
AC-1137550 VersaCut+ Disp. Kit w/o Tubes (6-Pack)
System Components Control unit with aspiration pump, Footswitch with integrated cable, Endoscope adapter set, Sterile
aspiration tubing, Drainage tube (non-sterile), Cleaning brushes, Sterilization tray, Regular handpiece
and blades, Inverted handpiece and blades, Disposable tissue collection container kit, Power cables
(one cable for North America systems, and one cable with a European plug).
Scope compatibility Minimum straight working channel diameter: ≥ 5 mm
Morcellation rate Approximately 9 grams / minute*
Control unit dimensions 33cm x 32.4cm x 14.3cm; 13in x 12.8in x 5.6in (LxWxH)
Control unit weight 6.6 Kg / 14.6 Lbs.
Handpieces dimensions
• Regular handpiece: 10.9cm x 4.4cm x 20.2cm; 4.3in x 1.7in x 7.8in (LxWxH)
• Inverted handpiece: 10.9cm x 4.8cm x 20.8cm; 4.3in x 1.9in x 8in (LxWxH)
Handpieces weight
• Regular handpiece: 0.7 Kg. / 1.5 Lbs.
• Inverted handpiece: 0.7 Kg. / 1.5 Lbs.
Electrical requirements 100-240 VAC, 2A, 50/60 Hz, single phase
*Based on a few human cases performed by Tev Aho, M.D., Consultant Urologist, Cambridge University NHS Trust, U.K.